大角嘴新盘「傲寓」首推50伙 折实价538.8万元起
其士集团(00025.HK)与市建局合作的大角嘴住宅项目「傲寓」公布首张价单,涉及50伙单位。当中有23伙开放式及27伙一房单位,实用面积介乎262至340平方尺。
项目定价介乎597万至797万元,尺价介乎20,374元至25,702元。计及最高9.75%折扣优惠,折实售价介乎538.8万至719.3万元,折实平均尺价20,934元。
其士集团销售及市务经理冼佩盈认为项目定价合理,相信是开心的安排。她坦言,疫情对开盘有少许影响,强调定价有顾及市场接受程度,料与市价有约10%折让,相信具竞争力。
她又指,会留意市场反应,若热烈的话不排除加价,计划在周末前收票,希望能在月底开售。(jc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.